Premium
Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease‐Modifying Antirheumatic Drugs
Author(s) -
Pappas Dimitrios A.,
Hooper Michele M.,
Kremer Joel M.,
Reed George,
Shan Ying,
Wenkert Deborah,
Greenberg Jeffrey D.,
Curtis Jeffrey R.
Publication year - 2015
Publication title -
arthritis care and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.032
H-Index - 163
eISSN - 2151-4658
pISSN - 2151-464X
DOI - 10.1002/acr.22628
Subject(s) - medicine , rheumatoid arthritis , hazard ratio , confidence interval , confounding , methotrexate , proportional hazards model , prednisone , incidence (geometry) , surgery , physics , optics
Objective To identify the rheumatoid arthritis (RA) characteristics associated with increased herpes zoster (HZ) risk in the Corrona registry RA patients, and to evaluate the risk in initiators of tumor necrosis factor inhibitors (TNFi) or non‐TNFi biologic agents or (among those who were currently on or had been previously treated with methotrexate [MTX]) conventional synthetic disease‐modifying antirheumatic drugs (csDMARDs) other than MTX. Methods Cox regression modeling estimated the association between first HZ incidence and selected RA characteristics, including disease activity. Medication‐related risk for HZ in RA patients taking current or past MTX (to exclude milder RA disease) were categorized by treatment initiation (TNFi versus non‐TNFi versus csDMARD). Hazard ratios (HRs) estimated HZ risk of each treatment initiation category after stratification on trimmed propensity score (PS) quintiles to control for potential confounders. Results A total of 28,852 patients contributed 95,287 person‐years. Seven hundred twenty‐nine observed HZ cases yielded a 7.7 (95% confidence interval [95% CI] 7.1–8.2) per 1,000 patient‐years crude incidence rate, lower than found in prior RA cohorts. However, consistent with prior studies, increasing age (HR 1.14, 95% CI 1.09–1.19 per 5 years) and prednisone therapy ≥7.5 mg/day (HR 1.81, 95% CI 1.23–2.67) were associated with a higher HZ risk. Referent to TNFi exposure, PS‐stratified analysis showed an HR for csDMARDs of 1.36 (95% CI 0.82–2.25) and for non‐TNFi of 0.83 (95% CI 0.51–1.38). Conclusion In the Corrona registry, the HZ risk in RA patients taking prior or current MTX increased with older age and higher prednisone dose. The HZ risk among these patients with RA was comparable after initiation of TNFi versus non‐TNFi versus csDMARDs.